These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 7513251)

  • 1. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non-Hodgkin's lymphomas. Results of alternating chemotherapy versus sequential chemotherapy].
    Avilés A; Díaz-Maqueo JC; Torras V; Rodríguez L; López Vancell D
    Sangre (Barc); 1990 Aug; 35(4):245-9. PubMed ID: 1703327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP.
    Steinke B; Bross K; Reinold HM; Heim ME; Schalk KP; Heidemann E; Josten K; Arnold H; Manegold C; Hoffman I
    Eur J Cancer; 1992; 28(1):100-4. PubMed ID: 1373634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
    Cabanillas F; Rodriguez-Diaz Pavón J; Hagemeister FB; McLaughlin P; Rodriguez MA; Romaguera JE; Dong K; Moon T
    Ann Oncol; 1998 May; 9(5):511-8. PubMed ID: 9653492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response-oriented therapy with CHOP and VIM-Bleo in high-grade malignant non-Hodgkin's lymphomas.
    Steinke B; Krüger HU; Kraft H; Heim ME; Günther E; Arnold H; Busch FW
    Blut; 1988 Jun; 56(6):269-71. PubMed ID: 2454690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sequential alternating chemotherapy of highly malignant non-Hodgkin's lymphomas with VIM-Bleo and CHOP. Initial results].
    Steinke B; Kraft A; Reinold HM; Heim ME; Löffler B; Heidemann E; Richter C; Josten K; Bross K; Hofmann I
    Onkologie; 1989 Feb; 12(1):19-21. PubMed ID: 2469999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy.
    Krol AD; Berenschot HW; Doekharan D; Henzen-Logmans S; van der Holt B; van 't Veer MB
    Radiother Oncol; 2001 Mar; 58(3):251-5. PubMed ID: 11230885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in chemotherapy for large cell lymphoma.
    Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients.
    Todeschini G; Ambrosetti A; Meneghini V; Pizzolo G; Menestrina F; Chilosi M; Benedetti F; Veneri D; Cetto GL; Perona G
    J Clin Oncol; 1990 May; 8(5):804-8. PubMed ID: 1692089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma.
    Armitage JO
    Ann Oncol; 1991 Jan; 2 Suppl 1():37-41. PubMed ID: 1710488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CHOP-bleo versus m-BACOD in the treatment of intermediate and high-grade malignant lymphomas].
    Avilés A; Huerta J; Guzmán R; Zepeda G; Díaz-Maqueo JC
    Rev Invest Clin; 1990; 42(4):271-6. PubMed ID: 1708910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stomach conservation in stages IE and IIE gastric non-Hodgkin's lymphoma.
    Maor MH; Velasquez WS; Fuller LM; Silvermintz KB
    J Clin Oncol; 1990 Feb; 8(2):266-71. PubMed ID: 1688927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
    Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
    Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
    McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
    Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
    J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.